Cidara Therapeutics, Inc.
CDTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.09 | 12.22 | 0.05 | -0.01 |
| FCF Yield | -1.58% | -5.41% | -7.19% | -11.25% |
| EV / EBITDA | -25.75 | -9.69 | -5.55 | -1.39 |
| Quality | ||||
| ROIC | -20.88% | -6.22% | -17.50% | -32.47% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.49 | 1.59 | 0.93 | 0.56 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -84.64% | -72.93% |
| Free Cash Flow Growth | 0.84% | -86.61% | 25.38% | 20.07% |
| Safety | ||||
| Net Debt / EBITDA | 3.29 | 19.78 | 6.56 | 3.44 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -8.70 | -7,353.33 | -8,994.49 | -3.90 |